Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

Item

http://www.wikidata.org/entity/Q36115580

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@ast

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@en

type

Item

label

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@ast

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@en

prefLabel

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@ast

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@en

P1476

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

@en

P2093

Cristiana Lo Nigro

http://www.w3.org/2001/XMLSchema#string

Cristina Granetto

http://www.w3.org/2001/XMLSchema#string

Daniela Vivenza

http://www.w3.org/2001/XMLSchema#string

Emanuela Miraglio

http://www.w3.org/2001/XMLSchema#string

Marco C Merlano

http://www.w3.org/2001/XMLSchema#string

Teresa Fabozzi

http://www.w3.org/2001/XMLSchema#string

Vincenzo Ricci

http://www.w3.org/2001/XMLSchema#string

P2860

The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

P304

6944-6954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V22.I30.6944

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27570430

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

biomarker

P932

4974592

http://www.w3.org/2001/XMLSchema#string